In the randomized Phase III RASolute 302 trial, daraxonrasib extended the median overall survival of 500 previously treated patients with metastatic pancreatic cancer from 6.7 months to 13.2 months, reduced the risk of death by 60%, with an HR of 0.40. The objective response rate confirmed in the ITT population was 31.6%.
Source:BIOENGINEER.ORG · Read the original
Leave a Reply